Cargando…

96. Assessing the Impact of the Meningitis/encephalitis Diagnostic Panel on Antimicrobial Stewardship

BACKGROUND: The multiplex polymerase chain reaction (PCR) test for meningitis/encephalitis (ME) is an assay that is available to detect 14 organisms in 2 hours from the cerebral spinal fluid. The primary objective was to assess the clinical impact of this assay on antimicrobial stewardship. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Garellek, Jonathan, Doan, Thien-Ly, Varghese, Shawn, Schwartz, Rebecca, Rasul, Rehana, Donaghy, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776856/
http://dx.doi.org/10.1093/ofid/ofaa439.141
_version_ 1783630778980106240
author Garellek, Jonathan
Doan, Thien-Ly
Varghese, Shawn
Schwartz, Rebecca
Rasul, Rehana
Donaghy, Henry
author_facet Garellek, Jonathan
Doan, Thien-Ly
Varghese, Shawn
Schwartz, Rebecca
Rasul, Rehana
Donaghy, Henry
author_sort Garellek, Jonathan
collection PubMed
description BACKGROUND: The multiplex polymerase chain reaction (PCR) test for meningitis/encephalitis (ME) is an assay that is available to detect 14 organisms in 2 hours from the cerebral spinal fluid. The primary objective was to assess the clinical impact of this assay on antimicrobial stewardship. METHODS: This is an IRB-approved, retrospective cohort study of a random sample of patients admitted between 7/2015 - 12/2018, stratified by season. A chart review was performed to collect: demographics, microbiology/treatment data, length of stay, hospital readmissions, and mortality. Differences for ME PCR versus culture only were assessed using Chi-square test or Fisher’s exact test. Time to de-escalation of empiric therapy was compared using the log-rank test. RESULTS: The study consisted of 241 patients, of whom 161 (66.8%) had CSF-PCR testing performed. Mean age was 51.76. There was an even distribution of males and females. Aside from patients with HIV, who were more represented in the standard period, there were no differences by comorbidity. The etiology of meningitis was greater in the PCR compared to the non-PCR group (10.5% vs. 2.5% in PCR and non-PCR respectively). Time to de-escalation of empiric therapy was significantly shorter in the PCR period (median [IQR]: 43.06 [26.9–47.7] vs. 64.62 [37.18–83.33], P< 0.004). Total days of therapy of antibiotics was longer among the PCR group, but not statistically significant (median [IQR] = 4 [1–7] vs. 2 [1–4], P=0.121). Median length of stay was higher in the PCR period compared to the standard group (median [IQR]: 9 [6 - 15] vs. 5.5 [3 - 8.5], P< 0.004). Readmission rates did not differ (PCR 13.7% vs. non-PCR 16.3%, P=0.592). More died during the PCR period (8.6% vs. 3.8%, P=0.16) but this was not statistically significant. CONCLUSION: The ME PCR was associated with an earlier time to antibiotics de-escalation. Patients that had the PCR test performed had more days of therapy and longer length of stay, but this is likely due to a higher rate of pathogen diagnosed. There was no association in readmissions. The initiation of rapid diagnostic testing in a healthcare settings has the potential to improve patient outcomes and may help antimicrobial stewardship by shortening the time to de-escalating antimicrobials and offering appropriate targeted therapy. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776856
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77768562021-01-07 96. Assessing the Impact of the Meningitis/encephalitis Diagnostic Panel on Antimicrobial Stewardship Garellek, Jonathan Doan, Thien-Ly Varghese, Shawn Schwartz, Rebecca Rasul, Rehana Donaghy, Henry Open Forum Infect Dis Poster Abstracts BACKGROUND: The multiplex polymerase chain reaction (PCR) test for meningitis/encephalitis (ME) is an assay that is available to detect 14 organisms in 2 hours from the cerebral spinal fluid. The primary objective was to assess the clinical impact of this assay on antimicrobial stewardship. METHODS: This is an IRB-approved, retrospective cohort study of a random sample of patients admitted between 7/2015 - 12/2018, stratified by season. A chart review was performed to collect: demographics, microbiology/treatment data, length of stay, hospital readmissions, and mortality. Differences for ME PCR versus culture only were assessed using Chi-square test or Fisher’s exact test. Time to de-escalation of empiric therapy was compared using the log-rank test. RESULTS: The study consisted of 241 patients, of whom 161 (66.8%) had CSF-PCR testing performed. Mean age was 51.76. There was an even distribution of males and females. Aside from patients with HIV, who were more represented in the standard period, there were no differences by comorbidity. The etiology of meningitis was greater in the PCR compared to the non-PCR group (10.5% vs. 2.5% in PCR and non-PCR respectively). Time to de-escalation of empiric therapy was significantly shorter in the PCR period (median [IQR]: 43.06 [26.9–47.7] vs. 64.62 [37.18–83.33], P< 0.004). Total days of therapy of antibiotics was longer among the PCR group, but not statistically significant (median [IQR] = 4 [1–7] vs. 2 [1–4], P=0.121). Median length of stay was higher in the PCR period compared to the standard group (median [IQR]: 9 [6 - 15] vs. 5.5 [3 - 8.5], P< 0.004). Readmission rates did not differ (PCR 13.7% vs. non-PCR 16.3%, P=0.592). More died during the PCR period (8.6% vs. 3.8%, P=0.16) but this was not statistically significant. CONCLUSION: The ME PCR was associated with an earlier time to antibiotics de-escalation. Patients that had the PCR test performed had more days of therapy and longer length of stay, but this is likely due to a higher rate of pathogen diagnosed. There was no association in readmissions. The initiation of rapid diagnostic testing in a healthcare settings has the potential to improve patient outcomes and may help antimicrobial stewardship by shortening the time to de-escalating antimicrobials and offering appropriate targeted therapy. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776856/ http://dx.doi.org/10.1093/ofid/ofaa439.141 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Garellek, Jonathan
Doan, Thien-Ly
Varghese, Shawn
Schwartz, Rebecca
Rasul, Rehana
Donaghy, Henry
96. Assessing the Impact of the Meningitis/encephalitis Diagnostic Panel on Antimicrobial Stewardship
title 96. Assessing the Impact of the Meningitis/encephalitis Diagnostic Panel on Antimicrobial Stewardship
title_full 96. Assessing the Impact of the Meningitis/encephalitis Diagnostic Panel on Antimicrobial Stewardship
title_fullStr 96. Assessing the Impact of the Meningitis/encephalitis Diagnostic Panel on Antimicrobial Stewardship
title_full_unstemmed 96. Assessing the Impact of the Meningitis/encephalitis Diagnostic Panel on Antimicrobial Stewardship
title_short 96. Assessing the Impact of the Meningitis/encephalitis Diagnostic Panel on Antimicrobial Stewardship
title_sort 96. assessing the impact of the meningitis/encephalitis diagnostic panel on antimicrobial stewardship
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776856/
http://dx.doi.org/10.1093/ofid/ofaa439.141
work_keys_str_mv AT garellekjonathan 96assessingtheimpactofthemeningitisencephalitisdiagnosticpanelonantimicrobialstewardship
AT doanthienly 96assessingtheimpactofthemeningitisencephalitisdiagnosticpanelonantimicrobialstewardship
AT vargheseshawn 96assessingtheimpactofthemeningitisencephalitisdiagnosticpanelonantimicrobialstewardship
AT schwartzrebecca 96assessingtheimpactofthemeningitisencephalitisdiagnosticpanelonantimicrobialstewardship
AT rasulrehana 96assessingtheimpactofthemeningitisencephalitisdiagnosticpanelonantimicrobialstewardship
AT donaghyhenry 96assessingtheimpactofthemeningitisencephalitisdiagnosticpanelonantimicrobialstewardship